CD274 and neoplasm: As PD-L1 expression in other tumor types shows variability at various time points [37], a major question remains if there is a therapeutic window for the optimal timing of immunotherapy, and if PD-L1 expression and response to immunotherapy is associated with previous treatment modalities (e.g. androgen deprivation, radio-, or chemotherapy).